Kovac has been looking for a larger partner to help in the Cove in 19 vaccine race, and on Thursday it announced in Alliance with drugmaker buyer The to say the move will help cure VAX seek regulatory approval for its experimental inoculation on distribute doses.

Kovac一直在尋找一個更大的合作伙伴，以幫助在庫夫在19疫苗的比賽中，並在週四宣佈在聯盟與製藥商買家The到說，此舉將有助於治療VAX尋求監管準許其實驗性接種上分發劑量。

Financial terms of the deal would not disclosed, but Cure back shares surged 14% following the news.

交易的財務條款不會披露，但Cure back股價在消息發佈後大漲14%。

The firm last month started a late stage clinical trial of its covert 19 candidate, its banking on the same technology that has allowed rivals including Madonna, to progress with their vaccines.

該公司上個月開始對其隱蔽的19名候選人進行後期臨床試驗，其銀行業務與包括麥當勞在內的競爭對手的疫苗進展相同的技術。

The collaboration echoes a similar deal by German Peer By and Tech, also a research focused biotech firm.

此次合作與德國Peer By和科技公司的類似交易相呼應，後者也是一家專注於研究的生物技術公司。

It last year agreed to collaborate with global giant Pfizer on its vaccine, which is now being rolled out globally.

去年，它與全球巨頭輝瑞公司達成合作，其疫苗現已在全球推廣。

NASDAQ listed Kovac has said it aims to produce up to 300 million doses in 2021 up to 600 million in 2022.

納斯達克上市的科威公司表示，其目標是在2021年生產出高達3億劑的產品，到2022年達到6億劑。

Last year, it was at the center of a dispute over alleged attempts by Donald Trump to gain access to the vaccine, but the company denied having received any US offers for the company or its assets ahead of any regulatory approval.

去年，它處於唐納德-特朗普據稱試圖獲得疫苗的爭議中心，但該公司否認在任何監管準許之前收到了美國對該公司或其資產的任何報價。

The European Union has secured over 400 million doses of the cure back shot.

歐盟已經獲得了超過4億劑的治療回針。